Averion International Corp.
225 Turnpike Road
Southborough,
MA 01772
United States - Map
Phone: 508-597-6000
Fax: 508-597-5856
Web Site: http://www.averionintl.com
| Averion International Corp., an international clinical research organization, focuses on providing clinical research services and solutions for the drug development lifecycle. The company offers strategic consulting, product agency registration support, trial design, site selection, project management, medical and site monitoring, data management, biostatistical analysis and reporting, pharmacovigilance, medical writing, and clinical trial management and consulting services for the clinical trials lifecycle. It also provides strategic research planning, regulatory planning, program planning/clinical trial design, site selection/patient recruitment, quality assurance and auditing, data monitoring and clinical endpoint committees, clinical site monitoring, and clinical project management services. The company serves pharmaceutical, biotechnology, and medical device industries. The company provides its services in the United States and Europe. Averion International Corp. is headquartered in Southborough, Massachusetts with additional offices in New York, Maryland, California, Switzerland, France, the Netherlands, the United Kingdom, Poland, the Russian Federation, Israel, Germany, Austria, Hungary, the Czech Republic, and Ukraine. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Markus H. Weissbach MD Ph.D, 53
Exec. Chairman |
$
344.00K | N/A | Dr. Philip T. Lavin Ph.D., 62
Co-Founder, Vice Chairman and Member of Exec. Committee |
$
325.00K | N/A | Dr. Gene Resnick M.D., 60
Founder, Chief Medical Officer and Exec. VP |
$
305.00K | N/A | Mr. Lawrence R. Hoffman CPA, Esq., 54
Chief Financial Officer and Principal Accounting Officer |
$
164.00K | N/A | Mr. Peter Gonze , 60
Pres |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.30% Nasdaq 
Profile
